Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kymera Therapeutics (KYMR) Current Deferred Revenue (2019 - 2025)

Kymera Therapeutics (KYMR) has disclosed Current Deferred Revenue for 7 consecutive years, with $34.4 million as the latest value for Q4 2025.

  • On a quarterly basis, Current Deferred Revenue rose 153.13% to $34.4 million in Q4 2025 year-over-year; TTM through Dec 2025 was $34.4 million, a 153.13% increase, with the full-year FY2025 number at $34.4 million, up 153.13% from a year prior.
  • Current Deferred Revenue was $34.4 million for Q4 2025 at Kymera Therapeutics, down from $37.2 million in the prior quarter.
  • In the past five years, Current Deferred Revenue ranged from a high of $134.9 million in Q2 2021 to a low of $11.5 million in Q1 2025.
  • A 5-year average of $53.2 million and a median of $38.9 million in 2023 define the central range for Current Deferred Revenue.
  • Peak YoY movement for Current Deferred Revenue: crashed 65.2% in 2023, then surged 153.13% in 2025.
  • Kymera Therapeutics' Current Deferred Revenue stood at $101.0 million in 2021, then tumbled by 65.1% to $35.3 million in 2022, then grew by 7.44% to $37.9 million in 2023, then crashed by 64.16% to $13.6 million in 2024, then soared by 153.13% to $34.4 million in 2025.
  • Per Business Quant, the three most recent readings for KYMR's Current Deferred Revenue are $34.4 million (Q4 2025), $37.2 million (Q3 2025), and $40.0 million (Q2 2025).